DoubleRainbow Biosciences

MA - LexingtonBiotechnology1 H-1B visas (FY2023)

Focus: DoubleRainbow Biosciences is a early-stage biotech company focused on drug discovery through genetic analysis of natural sources, with a rare disease therapeutic focus based in Lexington, MA.

Rare Diseases

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About DoubleRainbow Biosciences

AI assessmentNot Hiring

No open roles listed right now. Follow DoubleRainbow Biosciences to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

0/9 — Limited

Company HealthSolid

Pipeline

Early-stage

0 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

H-1B (2023): 1 approval

Visa Sponsorship

Sponsors Work Visas

Help build intelligence for DoubleRainbow Biosciences

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Opportunity to contribute to platform-based drug discovery in rare diseases, an underserved therapeutic area with high clinical and commercial value
Join a genetics-focused biotech at inflection point—early enough to shape science direction but with validated funding track record (1 H1B approval in 2023)
Work on novel discovery approach leveraging natural genetic variation, differentiating from traditional screening methods

Watch Out For

No active clinical pipeline (0 programs in trials) means early career risk; no near-term regulatory catalysts or de-risking events
Minimal public visibility—no publications, no active job postings, and limited data suggest either stealth-mode operations or early resource constraints
Undisclosed funding, employee count, and stage create uncertainty about runway, team size, and ability to scale research operations

Generated by Claude from DoubleRainbow Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

H-1B Petitions (FY2023)

Approved

Denied

100%

Rate

Source: USCIS H-1B Employer Data Hub

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo